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These guidelines have been developed in order to provide an overview and a set of broad-based key recommendations for the
managementofpatientswithbonesarcomasintheUK.Theyhavetakenintoconsiderationthemostup-to-datescientiﬁcliterature
along with the recent recommendations by the European Society of Medical Oncology. The principles of the NICE guidance on
both “improving outcomes for patients with sarcomas” and “improving outcomes with children and young people with cancer”
have been incorporated. As care evolves, it is acknowledged that these guidelines will need updating. The key recommendations
are that bone pain or a palpable mass should always lead to further investigation and patients with clinicoradiological ﬁndings
suggestive of a primary bone tumour should be sent to a reference centre. Patients should then have their care managed at such a
specialist centre by a fully accredited multidisciplinary team.
1.Introduction
1.1. Rationale and Objective of Guidelines. Bone sarcomas
are an uncommon group of malignancies. It was recognised
more than 20 years ago in England that management of bone
sarcomas should be centralised; this led to the recognition
of two supraregional centres by the National Specialist
Commissioning Advisory Group (NSCAG) [now National
Commissioning Group(NCG)]in1986.Untilnow,however,
there have been no clinical guidelines to document the
standard of care for patients with these tumours.
In the US, the National Comprehensive Cancer Network
(NCCN) bone sarcoma guidelines [1] are highly regarded
as are those developed by The European Society of Medical
Oncology (ESMO) in conjunction with EUROBONET [2–
4]. Using these documents as a framework, clinical manage-
ment guidelines for patients with bone sarcoma in the UK
weredrawnupbyconsensusundertheauspicesoftheBritish
Sarcoma Group (BSG). Levels of evidence [I–V] and grades
of recommendation [A–D] as used by the American Society
of Clinical Oncology [5] have been published recently in the
ESMO guidelines and are also referred to elsewhere [6, 7].
We have not included the levels of evidence in this paper.
These guidelines are not intended to be prescriptive, but
aim to educate and improve the quality of care for patients
with bone sarcomas by helping to identify and inform the
key decisions involved in their management. Equally, this
paper does not extend to rehabilitation, prosthetic services,
and palliation.
1.2. Methods. The NCCN and ESMO guidelines together
with the National Institute for Health and Clinical Excellence
(NICE) Improving Outcomes Guidance for people with
sarcoma [8] were used as the basis for discussion by the
group, adding or omitting detail only where it was clearly
agreed by consensus, in relation to UK speciﬁc issues. A
recent literature review has been included to ensure that
referencing is comprehensive.2 Sarcoma
1.3. Scope of Guidelines. The recommendations apply to all
bone sarcomas arising in any skeletal location.
These guidelines focus on clinical eﬀectiveness, giving a
picture of what treatments a specialist sarcoma multidisci-
plinary team (MDT) should have access to within the UK,
subject to some ﬂexibility to allow for evolving practice,
but they do not employ the same detailed analysis of cost
eﬀectivenessasNICE.Thismaterialcanbeconsideredtorep-
resent a broad consensus in 2010; however, we acknowledge
that it will require updating as treatment evolves.
2. Overview
2.1. Classiﬁcation and Clinical Presentation. Primary bone
tumours are rare, accounting for less than 1% of cancers
in adults [9]. There are on average 427 new cases per year
in England and Wales [8] Data from the Oﬃce of National
Statistics and Welsh Cancer Intelligence and Surveillance
Unit. They have a relatively high incidence in children
and adolescents (accounting for approximately 5% of all
childhood cancers in European Countries) [10], but can
arise at any age. Given their rarity, nonspecialised clinicians,
radiologists, and pathologists may ﬁnd them diﬃcult to
recognise. To avoid diagnostic and management diﬃculties
earlyreferraltoaspecialistMDTpriortobiopsyisimportant
[11].
In adulthood, metastatic carcinomas and haemopoietic
malignanciesinboneconsiderablyoutnumberprimarybone
tumours. Where there is diagnostic uncertainty, it should be
assumed that the patient has a primary bone sarcoma until
proven otherwise [12].
During a working lifetime, a General Practitioner (GP)
is unlikely to see a patient with a bone sarcoma. Delays
in diagnosis are, therefore, common and earlier diagnosis
would almost certainly lead to improved outcomes both in
terms of survival and less extensive surgery.
The most common symptom of a primary bone tumour
is pain which may be nonmechanical or night pain. The
presence of bone pain at night should always be considered
to be a “red ﬂag” symptom leading to further investigation.
The presence of bone swelling or a soft-tissue mass may
occur later. The average duration of symptoms is 3 months
although a history of 6 months or longer is not uncommon
[13–15]. The presence of pain or a palpable mass arising
from any bone should cause concern and lead to further
investigation of which a plain X-ray is the ﬁrst investigation
ofchoice.ThepresenceofanyofthefollowingontheX-rayis
suggestive, but not diagnostic of a bone tumour and should
also lead to further investigation:
(i) bone destruction,
(ii) new bone formation,
(iii) periosteal swelling,
(vi) soft tissue swelling.
The histological classiﬁcation of primary malignant
bone tumours according to the World Health Organisation
(WHO) is given in Table 1.
Although listed by the WHO as bone tumours, the
management of haemopoetic tumours of bone is beyond the
scope of these guidelines.
2.2. Epidemiology and Aetiology. Although there are a num-
ber of inherited and acquired factors associated with the
development of primary bone tumours, it is not possible to
identifyaparticularcauseinthemajorityofpatients[17,18].
2.2.1. Osteosarcoma. Osteosarcoma is the most frequent
primary cancer of bone (incidence 0.2-0.3/100,000/year) [2],
UK rates are 0.27/100,000 population in England [19]. There
is an average of between 124–150 cases per year in England
and Wales [8, 19]. The incidence is higher in adolescents
(0.8–1.1/100,000/year at age 15–19), where it accounts for
>10% of all solid cancers. The male-female ratio is 1.4:1
(UK data 1.1:1-NCIN) The majority arise in adolescence,
but some are linked to other pathologies in the seventh and
eighth decades of life [20].
Osteosarcoma usually arises in the metaphysis of an
extremity long bone, most commonly around the knee [21,
22]. Some tumours (predominantly in adults) arise in the
axial skeleton or craniofacial bones. Conventional osteosar-
coma, a high-grade malignancy, accounts for the majority
of osteosarcoma. Its most frequent subtypes are osteoblastic,
chondroblastic, and ﬁbroblastic. Other high-grade types are
telangiectatic, small cell, and high-grade surface osteosar-
coma. Low-grade central and parosteal osteosarcoma are
low-grade malignancies, while periosteal osteosarcoma is
an intermediate-grade chondroblastic osteosarcoma. Risk
factors for the occurrence of osteosarcoma include previous
radiation therapy, Paget’s disease of bone, and germ line
abnormalities such as the Li-Fraumeni syndrome, Werner
syndrome, Rothmund-Thomson syndrome, and familial
retinoblastoma [23, 24].
2.2.2. Ewing Sarcoma. Ewing sarcoma (including primitive
neuroectodermal tumour of bone) is the second most
common primary malignant bone cancer in children and
adolescents, but is also seen in adults. The median age
at diagnosis is also around 15 years and there is a male
predilection of 1.5:1 (UK data 1.2:1 NCIN). Ewing sar-
coma is diagnosed in children aged 0–20 at an incidence
of 0.3/100,000/year [UK all age standardised rates report
0.11-0.12/100,000 population in the UK (1979–2004)] with
approximately 65–75 new cases per year in the UK [8, 19].
The most frequent sites of involvement are the long bones,
pelvis, ribs, and vertebral column. It is less common in
peopleofChineseorBlackAfricanorigin.AllformsofEwing
sarcoma are high-grade tumours [3, 25].
2.2.3. Chondrosarcoma. Chondrosarcoma is one of the most
common bone sarcomas of adulthood, characterised by the
production of tumour cartilage [26]. The age standardised
incidence may be as high as 0.25/100,000 per year in males
and 0.2/100,000 in females per year [UK age standardised
rates report 0.19/100,000 population in the UK (NCIN)],
with the most common age being between 30–60 years [27].Sarcoma 3
Table 1: 2002 WHO classiﬁcation of malignant bone tumours [16].
Osteogenic tumours
Osteosarcoma 9180/3
Conventional 9180/3
Chondroblastic 9181/3
Fibroblastic 9182/3
Osteoblastic 9180/3
Telangiectatic 9183/3
Small cell 9185/3
Low-grade central 9187/3
Secondary 9180/3
Parosteal 9192/3
Periosteal 9193/3
High grade surface 9194/3
Ewing sarcoma/primitive neuroectodermal tumour Ewing sarcoma 9260/3
Cartilage
Chondrosarcoma 9220/3
Central, primary, and secondary 9220/3
Peripheral 9221/3
Diﬀerentiated 9243/3
Mesenchymal 9240/3
Clear cell 9242/3
Fibrogenic tumours Fibrosarcoma 8810/3
Fibrohistiocytic tumours
Haemopoietic tumours Plasma cell myeloma 9732/3
Malignant lymphoma, NOS 9590/3
Giant cell tumour Malignancy in giant cell tumour 9250/3
Notochordal tumours Chordoma 9370/3
Vascular tumours Angiosarcoma 9120/3
Smooth muscle tumours Leiomyosarcoma 8890/3
Lipogenic tumours Liposarcoma 8850/3
Miscellaneous tumours Adamantinoma 9261/3
There are approximately 100–120 new cases per year in the
UK [8].
Themajorityofprimarychondrosarcomasarelowrather
than high grade [28]. Most chondrosarcomas are located
in the long bones, but they also occur in ﬂat bones such
as pelvis, rib, and scapula. Chondrosarcoma can arise in
preexisting benign lesions such as osteochondroma and
enchondroma. In these circumstances, they are referred to
as secondary peripheral chondrosarcomas and secondary
chondrosarcomas, respectively.
Themajorityofchondrosarcomasareoftheconventional
subtype, but rarer subtypes include mesenchymal chon-
drosarcoma and clear cell chondrosarcoma. In rare circum-
stances, conventional chondrosarcomas can “dediﬀerentiate”
into a very high-grade tumour with a dismal prognosis so-
called dediﬀerentiated chondrosarcoma [26, 29, 30]M o s t
chondrosarcomas are solitary, but they can occur as multiple
lesions in patients with osteochondromatosis (hereditary
multiple exostoses) and enchondromatosis (Ollier’s disease).
The risk of malignancy in solitary enchondromas and
osteochondromas is uncertain, but it is increased when there
are multiple lesions.
2.2.4. Spindle Cell Sarcomas of Bone. Spindle cell sarcomas
of bone represent between 2% and 5% of primary bone
malignancies and include a variety of diagnostic groups
including ﬁbrosarcoma, malignant ﬁbrous histiocytoma
(MFH), leiomyosarcoma, and undiﬀerentiated sarcoma.
These tumours arise in a similar age group to chondrosar-
coma, but the skeletal distribution is more like that of
osteosarcoma. They typically present with pain and have
a high incidence of fracture at presentation. Radiological
characteristics include a punched out or lytic appearance.
Anassociationwithpre-existingdisease/abnormality(Paget’s
disease or bone infarct) or history of previous irradiation has
been reported. It is not unusual for a spindle cell sarcoma to
be found to be either a dediﬀerentiated chondrosarcoma or
an osteosarcoma after resection.
2.2.5. Other Bone Sarcomas. These include such entities as
adamantinoma and chordoma which both have speciﬁc
clinical presentation and management [16]. Adamantinoma
of bone typically arises in the anterior cortex of the diaphysis
of the tibia. Chordomas are rare, typically arising in the
sacrum or base of skull from notochord remnants.4 Sarcoma
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Figure 1: Age-speciﬁc incidence rates by morphology, England,
1979–2004.
Age-speciﬁc incidence rates by morphology are shown in
Figure 1.
3. DiagnosisandReferral
3.1. Early Steps in Diagnosis. In children under the age of 5
years, primary malignant bone tumours are rare. Between
the age of 5 and approximately 40, a primary malignant
bone tumour is likely to be the most common diagnosis
of a bone neoplasm in the absence of a past history of
malignancy. Over 40, the incidence of metastases (usually
from bronchus, breast, thyroid, kidney, or prostate) becomes
increasingly common. At any age, the possibility of a benign
lesion, infection, or haematological malignancy (plasma cell
tumor or lymphoma) must be considered.
In all patients a full clinical history (duration/intensity
of complaints, time points of pain during the day, prior
benign and malignant lesions, family history, and previous
radiotherapy) and examination (with speciﬁc attention to
size/consistency of swelling, location and relation of swelling
to bone, demarcation and mobility of swelling and palpation
of regional, and local lymph nodes) should be performed,
taking into account the most likely diagnoses listed above.
In patients under the age of 40, investigations prior to
referral should include X-ray of the aﬀected bone and chest
as well as simple blood tests [(full blood count (FBC),
erythrocyte sedimentation rate (ESR), biochemical proﬁle
including alkaline phosphatase (ALP)]. Magnetic resonance
imaging (MRI) can be done prior to or after referral [15].
In patients over the age of 40, where metastatic disease
is more common, patients should be more extensively
investigated to exclude a primary tumour at another loca-
tion, ideally with computed tomography (CT) of the chest,
abdomen and pelvis, isotope bone scan, and a myeloma
screen prior to referral—provided these can be done quickly.
If the lesion is solitary and no primary site identiﬁed, then
the patient should be referred to one of the reference centres.
All patients with clinicoradiological ﬁndings suggestive
of a primary bone tumour should be sent to a bone tumour
reference centre prior to biopsy. In England, there are ﬁve
designated centres.
3.2. UK Reference Centres.
(i) Royal National Orthopaedic Hospital: London,
phone02089095584/5600,fax02089095709,http://
www.londonsarcoma.org.
(ii) Royal Orthopaedic Hospital: Birmingham, phone
0121 685 4150, Fax 0121 685 4146.
(iii) Nuﬃeld Orthopaedic Centre: Oxford, phone 01865
738061.
(iv) North of England Bone and Soft Tissue Tumour
Service, Freeman Hospital: Newcastle upon Tyne
phone 0191 223 1496, fax 0191 233 1328, http://www
.newcastlesarcoma.org.uk.
(v) Greater Manchester and Oswestry Sarcoma Service,
Robert Jones and Agnes Hunt Hospital: Oswestry,
phone 0845 838 3429, fax 0845 838 3428.
3.3. Management at Reference Centre. All patients with a
suspected bone sarcoma should be referred for diagnosis
and have their care managed at a reference centre by a fully
accredited multi disciplinary team (MDT) [31, 32]. This is a
core principle of the NICE Guidance “improving outcomes
for patients with sarcomas” [8] and “improving outcomes
with children and young people with cancer” [33]. This
guidance also recommends the following.
(i) Networks should ensure that GPs are aware of and
comply with the urgent referral criteria in the NICE
“referral guidelines for suspected cancer” and that
GPs and hospital doctors are aware of the diagnostic
pathways.
(ii) All patients with a conﬁrmed diagnosis of bone
sarcoma should have their care supervised by or in
conjunction with a sarcoma MDT and be allocated
a key worker. Children, teenagers, and young adults
should also be discussed at the relevant children’s or
TYA (young adult) MDT.
(a) Networks should ensure that they meet the
needs of children and young people with cancer
with suﬃcient specialist staﬀ and care and
facilities appropriate to the child or young
persons age.
(iii) AbonesarcomaMDTshouldmeetminimumcriteria
for the number of patients treated in each year and
adhere to the requirements for core membership of
the relevant specialties.
(a) All sarcoma MDTs should collect data on
patients, tumours, treatment, and outcomes as
agreed nationally.
(iv) All patients with a provisional histological and/or
radiological diagnosis of bone sarcoma should have
their diagnosis reviewed by a specialist sarcoma
pathologist and/or radiologist who are part of a
sarcoma MDT.Sarcoma 5
(v) Patients should undergo deﬁnitive resection of their
s a r c o m ab yas u r g e o nw h oi sam e m b e ro fas a r c o m a
MDT or by a surgeon with tumour site-speciﬁc
or age-appropriate skills, in consultation with the
sarcoma MDT.
(vi) Chemotherapy and radiotherapy are important com-
ponentsofthetreatmentofsomepatientsandshould
be carried out at designated centres by appropriate
specialists as recommended by a sarcoma MDT.
(vii) Patients should be informed about relevant clinical
trials and supported to enter them.
Furthermore, referral of patients to the reference centre
forinitialbiopsyisalsostronglyrecommended.Thisobviates
the risk associated with improperly performed biopsies and
increases the proportion of patients whose tumours can be
studied with modern molecular techniques.
4. Investigation
4.1. Imaging. All patients should have plain X-rays in two
planes at presentation. CT should only be used in cases
where there is diagnostic uncertainty and to optimally visu-
alise areas of microcalciﬁcation, periosteal bone formation,
cortical destruction, or soft tissue involvement. CT can also
be helpful for surgical planning in the pelvic area. When
the diagnosis of malignancy is possible on radiographs, MRI
of the whole bone is the next most appropriate imaging
investigation and is the best modality for local staging [34].
General staging (where indicated) to assess the extent
of distant disease should include chest radiography and/or
CT. CT remains the diagnostic technique of choice for
imaging the chest [35], (appreciating that small nodules are
not speciﬁc for malignancy). Whole body bone scintigraphy
will detect lesions elsewhere in the skeleton [3]. Whole
body MRI and positron emission tomography (PET) are
under evaluation both for staging and treatment response
evaluation [36]. Additional appropriate imaging studies and
biopsies should be taken of suspicious sites, as accurate
staging of the disease has an impact on treatment and
outcome. Guidance on the management of small suspicious
lung nodules is available in trial protocols [37, 38].
In the case of chondrosarcoma, a contrast enhanced MRI
can reveal high-grade areas, which is useful to guide the site
of biopsy.
4.2. Staging. There are two common staging systems in use,
the Enneking [39] and the TNM system (American Joint
Committee on Cancer-AJCC/International Union against
cancer-UICC) [40].
The Enneking system is based on tumour grade (I = low
and II = high grade) and extent in relation to the anatomical
compartments of the limb. Where the bone cortex is intact,
the tumour is deemed to be intracompartmental. Stage
III tumours can be any grade with metastases. This is
summarized in Table 2.
The TNM (AJCC/UICC) system is based on tumour
grade, size, and the presence of metastases (Table 3).
4.3. Laboratory Tests. No speciﬁc laboratory tests for diag-
nosis of bone sarcoma are available. However, some may
be of prognostic value; examples include ESR, alkaline
phosphatase (ALP) and lactate dehydrogenase (LDH) [41,
42].
4.4. Other Baseline Assessments. Chemotherapy treatment
can result in renal, cardiac, and auditory dysfunction [43],
and patients undergoing this treatment must have baseline
renal function testing and assessment of cardiac function as
well as an audiogram (in case of treatment with cisplatin).
Sperm storage is recommended for male patients of repro-
ductive age. For female patients, a fertility physician should
be consulted to discuss options with the patient.
4.5. Biopsy. The deﬁnitive test remains biopsy. The biopsy
of a suspected primary malignant bone tumour should be
carried out at the reference centre by the surgical team
who are to carry out the deﬁnitive tumour resection.
Inappropriate techniques can irrevocably compromise the
chance of limb salvage or even cure. The principles of biopsy
[11] are the following:
(i) Biopsy should only be done after local imaging of
the aﬀected bone to allow planning of the most
representative area to biopsy.
(ii) There should be minimal contamination of normal
tissues.
(iii) In many situations, core needle biopsy will be
adequate, often controlled by ultrasound, X-ray or
CT.
(iv) Samples should always be taken for micro biological
culture as well as histology and cytogenetic studies.
(v) In the reference centre, samples should ideally be
snap frozen for storage in a tumour bank for future
translational research studies (patient consent should
be obtained).
(vi) Samples must be interpreted by an experienced
pathologist.
(vii) The request form should contain suﬃcient detail for
a pathologist to make a diagnosis, including the site
of the tumour, the patient’s age, and the radiological
diﬀerential diagnosis.
CT guided biopsies [44, 45] are appropriate for deeper
locations(e.g.,pelvis)ortotargetaparticularareaofconcern
(e.g., a possibly dediﬀerentiated area in a chondrosarcoma).
Incasesofuncertaintythatthetissueisrepresentative,frozen
section may be considered in case more material is required.
In aggressive and malignant tumours of bone, the biopsy
track should be considered to be contaminated with tumour
and must be removed together with the resection specimen
at deﬁnitive surgery to avoid local recurrence; this includes
possible channels through which drains have been placed.
Biopsy tracks should be clearly marked by means of a small
incision to ensure that the location can be recognised at the
deﬁnitive procedure.6 Sarcoma
Table 2: Enneking staging.
Stage Grade Tumour Metastasis
IA G1 low grade T1 cortex intact (intracompartmental) M0
IB G1 low grade T2 cortex breached with soft tissue extension M0
IIA G2 high grade T1 cortex intact M0
IIB G2 high grade T2 cortex breached with soft tissue extension M0
IIIA G1 or G2 T1 M1
IIIB G1 or G2 T2 M1
Table 3: AJCC/UICC staging.
Stage Tumour (T) Node (N) Metastasis (M) Grade (G)
Stage IA T1 (tumour 8cm or less) No M0 G1, 2 low grade
Stage IB T2 (tumour more than 8cm) No M0 G1, 2 low grade
Stage IIA T1 No M0 G3, 4 high grade
Stage IIB T2 No M0 G3, 4 high grade
Stage III T3 (discontinuous tumours in primary site) No M0 Any G
S t a g eI V A A n yT N o M 1 a( l u n g ) A n yG
Stage IVB Any T N1 (regional lymph nodes) Any M Any G
Any T Any N M1b (other sites) Any G
Biopsy of other indeterminate lesions should always be
considered if it will aﬀect patient management (e.g., entry
into a trial or local control decisions).
In cases of spinal column involvement, laminectomy or
decompression should be avoided unless necessary to relieve
spinal cord compression, and only after consultation with
members of the bone sarcoma MDT.
4.6. Pathology. The pathologist reporting on both the diag-
nosisandresectionofbonesarcomasshouldbeanaccredited
bone tumour pathologist and part of a bone sarcoma MDT.
The report should comply with guidance from the Royal
College of Pathologists [46].
The biopsy report should include a description of the
specimen received and the microscopic ﬁndings including
the histological diagnosis. Histopathology reports of resec-
tion specimens should include a gross specimen description
which records the location and size (measured in three
dimensions in mm) of the tumour in the resected bone. The
histological features of the tumour should be described and
the tumour type (and subtype) classiﬁed according to the
latest WHO criteria [16]. The pathology report should note
the extent of local tumour spread, including involvement
of speciﬁc anatomical compartments. Whether the resection
margins are clear or involved should be noted and the
distance (in mm) of inﬁltrating tumour from the nearest
resection margin and the nature of tissue at this resection
margin speciﬁed. Results of relevant ancillary investigations
(e.g. immunohistochemistry or molecular genetics) should
be recorded and the tumour should be coded using the
Systematized Nomenclature of Medicine—Clinical Terms
(SNOMED-CT) codes [47].
The extent of tumor necrosis in response to any preop-
erative therapy should be assessed as being greater or less
than 90% necrosis in broad terms although much greater
speciﬁcity can be obtained.
4.7. Molecular Genetics and Pathology. Tumour banks are
instrumental for diagnostic and translational research in the
molecular pathology of cancer; therefore, informed consent
for tumour banking should be sought that allows for later
analysis and research according to local practice. In specialist
centres, storage of fresh frozen tissue should be undertaken
in every case where consent has been given.
Although most Ewing sarcomas can be recognised mor-
phologically and by immunohistochemistry for the surface
glycoprotein CD99, Ewing sarcoma translocation detection
is mandatory when the clinicopathological presentation is
unusual or the histological diagnosis is doubtful. A reference
laboratory for Ewing sarcoma diagnosis should have both
interphase ﬂuorescence in situ hybridisation (FISH) and
reverse transcription-polymerase chain reaction (RT-PCR)
technology available [48]. The laboratory should be a
participant in an external quality assurance programme.
4.8. Conﬁrmation of Diagnosis. In every case, the diagnosis
must be conﬁrmed by reference to clinical ﬁndings, labo-
ratory investigation and, in particular, radiological imaging
at a sarcoma MDT. Ideally, all patients with suspected bone
tumours should be discussed at the MDT meeting with theSarcoma 7
surgeon,theradiologistwhohasinterpretedtheimagingand
the pathologist who has reviewed the biopsy material and
an oncologist [8]; this will minimise the risk of errors in
diagnosis and management.
5. Prognostic Factors
5.1. Osteosarcoma. Estimates of patients with newly diag-
nosed osteosarcoma with metastases, mainly located in
the lung [14, 49, 50], vary from 12.4%–34.4% rising to
40% of all cases over time [51]. Microscopic, subclinical
metastatic disease is present in the majority of patients at
diagnosis. Adverse prognostic or predictive factors include
detectable primary metastases as well as axial or proxi-
mal extremity tumour site, large tumour volume, elevated
serum alkaline phosphatase or LDH, older age, and poor
histological response to preoperative chemotherapy/level of
chemotherapy induced necrosis [41, 52].
5.2. Ewing Sarcoma. Around 26% of patients are diagnosed
withmetastaticdisease(10%lung,10%bones/bonemarrow,
6% combinations, or others) [25]. Bone metastases confer
a poorer outcome than lung/pleura metastases (<21% com-
pared with 55% 5-year relapse free survival) [53]. Other
known prognostic factors are tumour site/axial location or
volume, raised serum LDH levels and older age (>15 years).
A poor histological response to preoperative chemotherapy
and incomplete or no surgery for local therapy are further
adverse prognostic factors [42, 52, 54, 55].
5.3. Chondrosarcoma. All chondrosarcomas have a signiﬁ-
cant risk of local recurrence, but metastases rarely arise in
patients with grade I tumours. Grade II and III chondrosar-
comasareoftengroupedtogethereventhoughthereisawide
spectrum of outcome—grade and stage are independent
prognostic factors [56] along with histology [27]. Clear cell
chondrosarcoma behaves like a low-grade chondrosarcoma,
whilst mesenchymal chondrosarcoma should be considered
a high-grade bone sarcoma. Dediﬀerentiated chondrosar-
comas are high-grade aggressive sarcomas and frequently
metastasise to lungs and other bones [26, 30].
5.4. Spindle Cell Sarcomas of Bone. Prognosis is similar to
patients with osteosarcoma of the same age and is related to
the same prognostic factors.
6. Management Overview
Bone sarcoma is a potentially curable disease with surgery
and chemotherapy being the mainstays of treatment-
notably preoperative “neoadjuvant” systemic combination
chemotherapy, local surgery, and postoperative “adjuvant”
chemotherapy [43]. One of the main goals is to decrease
the incidence of a subsequent distant relapse [57]. Despite a
lack of new treatments over time, outcomes have improved,
due to use of more aggressive multimodal treatments
and utilisation of surgery for sites previously considered
inoperable [58].
Survival for patients with bone tumours has improved
substantiallyoverthelast30yearsintheUK.Anationalstudy
looking at the survival of patients aged 15 years or older with
bone cancer of all types found that 5-year relative survival
rates increased from 29% in 1971–1975 to 51% in1986–1990
[59]. Patterns of survival for patients under 40 in the UK
showed an increase from 42% to 53% in the period from the
early ‘80s to the early ‘90s for osteosarcoma and 31% to 51%
for Ewing sarcoma [60]. The EUROCARE data for children
aged 0–14 years showed an increase from 52% to 60% for
osteosarcoma, and 50% to 60% for Ewing sarcoma during
the latter 4 years of a survey performed between 1978 and
1989 when compared to the entire 11 year period [10]. Data
fromnorthernEnglandandtheWestMidlandsfortheperiod
1981–2002 showed an improvement for Ewing sarcoma but
not for osteosarcoma for a number of reasons including
potential delays in diagnosis, accrual to trials, adherence to
therapy and lack of improvement in treatment strategies
[17].
6.1. Systemic Chemotherapy. As malignant primary bone
tumours are rare and management is complex, the accepted
standard is treatment in reference centres or within reference
networks able to provide access to the full spectrum of care
in predetermined partnerships with such centres [2, 8].
Therapy is usually given within the framework of
prospective, often collaborative, clinical studies, or estab-
lished treatment protocols. In cases of high-grade osteosar-
coma, Ewing sarcoma or spindle cell sarcoma (neo) adjuvant
therapy is indicated, preferably within the framework of
international clinical trials.
6.2. Surgery. Surgery of the primary tumour should be
performed only after adequate preoperative staging, striving
to obtain adequate surgical margins. A wide enbloc resection
of the aﬀected part of the bone and soft tissue should be
performed. Close surgical margins may be identiﬁed with
(MRI-inert) haemoclips.
Decisions about the optimal surgical procedure (i.e.,
limb salvage or amputation) should be made as part of an
MDT discussion, taking into account tumour and treatment
factors (e.g., extent of tumour and response to neoadjuvant
therapy). The type of surgical reconstruction will depend on
patient and surgeon choice and experience following open
discussion of the risks and beneﬁts of diﬀerent options.
Surgical excision of local recurrence or metastatic disease
should usually be considered following decisions being made
by the MDT.
6.2.1. Requirements for the Surgical Report. The surgeon
should describe the surgical procedure carried out and indi-
cate the tissues resected. The planned surgical margin should
be identiﬁed along with any areas of concern. The type of
reconstruction should be described and the postoperative
care to be used. The use of prophylactic antibiotics and
anticoagulantsshouldbeclearlystated.Thespecimenshould
be orientated to allow the pathologist to adequately describe
the anatomical location of close surgical margins.8 Sarcoma
6.3. Radiotherapy. The role of radiotherapy in osteosarcoma
and chondrosarcoma is limited, as these tumours are recog-
nised as being relatively radioresistant. Thus, radiotherapy is
onlyusedasdeﬁnitivetreatmentofaprimarytumourifthere
is no surgical option. It can be usefully used to achieve local
tumour control at least in the short to mid-term although
it is unlikely to achieve long term tumour control. However,
there is limited evidence that osteosarcoma can sometimes
be controlled by radiotherapy alone if there has been a good
subjective response to chemotherapy [61]. If radiotherapy
is to be used as deﬁnitive local treatment, a radical dose of
radiotherapy is required. Standard conformal radiotherapy
may not be able to achieve an adequate radiotherapy dose to
the tumour, in which case techniques such as IMRT (inten-
sity modulated radiotherapy) may allow delivery of a higher
radiotherapydose[62].Inaddition,insertionofpelvicspacer
devices can enable displacement of bowel away from pelvic
tumours, which can also facilitate delivery of a higher dose.
Heavy particle therapy with protons or carbon ions, often
in combination with photons, are being used increasingly
in the treatment of primary bone sarcomas not amenable to
surgery [63–65]. Excellent outcomes have been reported for
skull base chondrosarcomas with proton beam radiotherapy
achieving approximately 70%–90% local control rates when
combined with surgery [66], and the reported early results
in bone sarcomasare encouraging. However, this approach is
stillrelativelynewandisconsideredatpresentasexploratory.
At present, there is no proton facility in the United Kingdom,
but potentially suitable cases can be submitted to the UK
Proton Panel for consideration for approval for funding for
treatment at a facility overseas.
Radiotherapy may be used postoperatively in osteosar-
coma and chondrosarcoma in selected cases, if there are
concerns regarding (usually soft tissue) resections margins,
or possible soft tissue contamination, and if further surgery
is not possible [63].
In contrast with osteosarcoma and chondrosarcoma,
Ewing Sarcoma is undoubtedly a radiation-sensitive tumour,
and as such, radiotherapy can be usefully utilised as part of
management. It may be used as deﬁnitive local therapy if
surgery is not possible, with curative intent. It may also be
used in combination with surgery, for patients who have had
a poor histological response to chemotherapy, or when there
are concerns regarding surgical resection margins [67, 68].
There is also a potential role for whole lung radiotherapy
(WLRT) for patients with lung metastases [69, 70], and
indeed, WLRT is included as part of treatment for patients
with lung metastases in the current Euro-Ewing-99 protocol.
Radiotherapy can be used for all bone sarcoma types for
palliation of metastatic disease.
6.4. Prevention and Management of Pathological Fracture.
Where there is an existing pathological fracture in a pos-
sibly malignant primary bone tumour, adequate imaging
should be performed including MRI followed by biopsy. In
cases of fracture, internal ﬁxation is contraindicated as it
disseminates tumour further into both bone and soft tissues
and increases the risk of local recurrence. External splintage
is recommended, along with appropriate pain control. In
patients with weakened bone apparent at presentation, there
may also be a strong case for immobilising the part after
biopsy.
Neoadjuvant chemotherapy should be used in the
expectation that a good response will allow the fracture
haematoma to contract and allow subsequent resection of
the tumour and the involved soft tissues. In patients with
a poor response to chemotherapy, or tumours unlikely
to respond to chemotherapy then early surgery obtaining
wide margins should be considered, which may require
amputation. Postoperative radiotherapy may be considered
to try to decrease the risk of local recurrence [71].
7. Speciﬁc Treatment
7.1. Osteosarcoma
7.1.1. Localised Disease. Curative treatment for high-grade
osteosarcoma consists of surgery and chemotherapy [2,
43]. Compared with surgery alone, multimodal treatment
of high-grade osteosarcoma increases survival probabilities
from only 10%–20% to around 60% [72].
Thegoalofsurgeryistosafelyremovethetumourandyet
preserve as much function as possible. Most patients should
be considered candidates for limb salvage. Wide surgical
margins should be planned accepting that an apparent good
response of the tumour to chemotherapy may allow a closer
margin of excision to be considered safe.
Doxorubicin, cisplatin, high-dose methotrexate, and
ifosfamide have demonstrated antitumour activity in
osteosarcoma [31, 72–75] and are usually administered in
protocols involving 3 or 4 drug combinations. These drugs
should be administered with adequate supportive care by
experienced paediatric oncologists or medical oncologists in
reference institutions with appropriate infrastructure with
a MDT approach [43]. A variety of pre- and postoperative
combinations are used in common practice and in clinical
trials, and the ideal combination regimen and the optimal
treatmentdurationareyettobedeﬁnedorconﬁrmed[2,76].
Most current protocols include a period of preoperative
chemotherapy. This has not been proven to add survival
beneﬁt over postoperative chemotherapy alone, although
there are clear practical advantages [31, 77]. Treatment is
commonly given over periods of 6–9 months. The extent of
histologicalresponsetopreoperativechemotherapyhowever
oﬀers important prognostic information [78], but altering
postoperative chemotherapy on the basis of response is
not recommended outside of ongoing trials [38], and it is
not accepted as a reliable surrogate endpoint for overall
outcome [43, 72]. The use of haematopoietic growth factors
to increase dose intensity has not consistently resulted in
improved survival of osteosarcoma patients [72]b u tm a y
limit morbidity associated with myelosuppression.
The immune modulator liposomal muramyl tripep-
tide (mifamurtide) added to postoperative chemotherapy
demonstrated a statistically signiﬁcant advantage in overall
s u r v i v a la n dat r e n di ne v e n t - f r e es u r v i v a li nal a r g e
randomised trial [79] and has been approved in EuropeSarcoma 9
for patients under 30 with completely resected localised
osteosarcoma.
Whenever possible, patients with osteosarcoma should
receive chemotherapy in the context of prospective trials,
which is regarded as standard of care. Chemotherapy is also
recommended for older patients with osteosarcoma using
adapted protocols [20].
Low-grade central and parosteal osteosarcoma are vari-
ants with lower malignant potential, which are treated
by surgery only. Careful analysis of the resected tumour
may show areas of high-grade change in which case the
patient should be treated as for a conventional osteosarcoma.
The exact role of chemotherapy has not been deﬁned for
periosteal and jaw osteosarcoma, but experience has shown
that chemotherapy can be given as standard. Jaw and other
craniofacial osteosarcomas present speciﬁc problems for
management, especially to achieve local control and should
always be referred to a reference centre and discussed at a
sarcoma MDT before surgical intervention.
7.1.2. Metastatic and Recurrent Disease. Patients presenting
with metastatic osteosarcoma are a heterogeneous group
and may be treated using the same regimens used for non-
metastatic osteosarcomas provided that surgical resection of
all sites of disease is deemed feasible [80]. Approximately
30% of all patients with primary metastatic osteosarcoma
and >40% of those who achieve a complete surgical remis-
sion become long-term survivors [2].
The management of recurrent osteosarcoma needs to
take into account the timing of recurrence, the site of
recurrence, and the number of metastases. Treatment for
recurrent osteosarcoma is primarily surgical, be it local
recurrence or metastatic. Prognosis is poor, with long-term
postrelapse survival of less than a third [2].
Pulmonary metastasectomy can play a major role but
only if complete removal of all metastases can be achieved
[51],asthediseaseisotherwisealmostuniversallyfatal.More
than a third of patients with a second surgical remission
survive for >5 years, even patients with multiple recurrences
may be cured as long as recurrences are resectable, and
repeated thoracotomies are often warranted [81].
The role of second-line chemotherapy for recurrent
osteosarcoma is less well deﬁned than that of surgery, and
there is no accepted standard regimen [2, 81]. The choice of
agents may take into account the prior disease-free interval
and often includes ifosfamide ± etoposide, or possibly
docetaxel/gemcitabine.Theuseofsecond-linechemotherapy
has been shown to correlate with limited prolongation of
survival in patients with inoperable metastatic recurrences,
and a positive correlation in operable disease was observed
in one series [82–84]. Radiotherapy to inoperable sites may
be indicated for palliation.
7.2. Ewing Sarcoma
7.2.1. Localised Disease. With surgery or radiotherapy alone,
5-year survival is <10%. With treatment in current multi-
modality trials including chemotherapy, 5-year survival is
∼60%–70% in localised and ∼20%–40% in metastatic
disease [3].
All current trials employ three to six cycles of initial
chemotherapy after biopsy, followed by local therapy and
another six to ten cycles of chemotherapy usually given at
2 or 3 week intervals based on current agreed national or
international protocols. Treatment duration is thus 10–12
months. Agents considered most active include doxorubicin,
cyclophosphamide, ifosfamide, vincristine, dactinomycin,
and etoposide [25, 37, 52, 54, 68, 69, 85–90]. Virtually all
active protocols are based on four to six drug combinations
of these agents. Chemotherapy intensity is positively asso-
ciated with outcome. High-dose chemotherapy with blood
stem cell transplantation is still investigational.
Despite lively debate, complete surgery, where feasible,
is regarded as the best modality of local control given the
higher risk of local recurrence when radiotherapy is used as
sole treatment for the primary tumour. Radiotherapy alone
should be considered if complete surgery is impossible or
if it will be very disabling. Individual decisions about local
therapy are frequently complex and should only be made by
an experienced reference centre MDT in conjunction with
the parents and family.
Postoperative radiotherapy should be given in cases of
inadequatesurgicalmarginsanddiscussedwherehistological
responseinthesurgicalspecimenwaspoor(i.e.,>10%viable
tumour cells). Tolerability of therapies in adults needs to be
taken into account when transferring treatment protocols
conceived for children and adults ≤40 years.
7.2.2. Metastatic and Recurrent Disease. Patients with metas-
tases at diagnosis are treated similarly to patients with
localised disease but have a worse prognosis. Several non-
randomised trials have assessed the value of more intensive,
time compressed or high-dose chemotherapy approaches,
followed by autologous stem cell rescue, but evidence of
beneﬁt, resulting from trials, is pending [70, 91, 92]. In
patients with lung metastases, whole lung irradiation may
confer a survival advantage but ﬁrm data are lacking and a
systematicreviewfailedtoconﬁrmasurvivaladvantage[93].
The role of surgical resection of residual metastases is less
well deﬁned. Patients with bone or bone marrow metastases
and patients with recurrent disease still fare poorly, with 5-
year survival rates of ∼20% [3, 94].
Prognostic factors relate to site of and time to relapse:
patients relapsing later than 2 years from initial diagnosis
and with disease not involving bone marrow or multiple
bones have a better outcome [95, 96]. Doxorubicin therapy
is usually no longer feasible due to previously achieved
cumulative doses. Chemotherapy regimens in relapse situa-
tions are not standardised and are currently often based on
alkylating agents (cyclophosphamide, high-dose ifosfamide)
in combination with topoisomerase inhibitors (etoposide,
topotecan) or irinotecan with temozolomide. [85, 90].
Radiotherapy may be helpful to palliate local symptoms.
7.3. Chondrosarcoma. Assessing the grade of chondrosarco-
mas is diﬃcult and variations in opinions, even between10 Sarcoma
experts are common [28]. Low-grade cartilage tumours
are unlikely to metastasise but may recur locally. Biopsy
conﬁrmed low grade central chondrosarcomas in the long
bones of the limbs can be managed by curettage with
or without adjuvant (e.g., phenol, cement, and cryother-
apy) with a high chance of success. Low-grade peripheral
chondrosarcomas (arising from osteochondromas) should
be surgically excised, aiming to excise the tumour with
a covering of normal tissue over it. Higher-grade chon-
drosarcomas (including clear cell chondrosarcoma), and all
chondrosarcomas of the pelvis or axial skeleton should be
surgically excised with wide margins [26, 29].
Recent evidence suggests that mesenchymal chondrosar-
coma may be responsive to chemotherapy and may be
considered for adjuvant or neoadjuvant therapy [97, 98].
Thereremainsuncertaintyaboutchemotherapysensitivityof
de-diﬀerentiated chondrosarcoma but it is often treated like
osteosarcoma,withpooreroutcome[30].Thereisaveryhigh
risk of local recurrence following excision of dediﬀerentiated
chondrosarcoma, particularly in the presence of a pathologi-
cal fracture. If wide margins cannot be reliably achieved with
limb salvage then amputation may be considered but the
metastases remain a problem.
7.4. Spindle Cell Sarcomas of Bone. Treatment strategies
mimic those of osteosarcoma, with age-adjusted chemother-
apy and complete enbloc resection including any soft-tissue
component.
7.5. Other Bone Sarcomas. Although conventional therapy
for chordomas has in the past been complete surgical
resection [99], there are encouraging results from high-dose
radiotherapy using proton beams or carbon ion facilities
[100, 101]. Assessment in a specialist centre with expertise
in managing these tumours is essential to deﬁne the role of
surgery and/or radiotherapy. Metastases are rare but local
recurrence common. There is evidence of some eﬀectiveness
of molecular targeted agents [102].
Most adamantinomas are low-grade but will recur if not
completelyresected.Higher-gradeareaseitherintheprimary
tumour or in the recurrence may require systemic therapy.
8. Treatment Evaluation
Imaging whilst the patient is on chemotherapy is limited
to intermittent assessment of the primary and metastatic
sites of bone disease by clinical means (pain and clinical
measurement) conventional radiographs, and assessment of
the lungs by CT [34].
8.1. Osteosarcoma. Change in the size and ossiﬁcation of
the tumour is not a reliable guide to tumour response to
neoadjuvant chemotherapy. Assessment of MRI detected
peritumouraloedemaishelpful:itsdisappearanceisasignof
a good treatment response [103]. Dynamic MRI is reliable,
but requires sequential scans to evaluate change in tumour
vascularity [104]. Assessment of response is usually only
apparent after several cycles of chemotherapy.
8.2. Ewing Sarcoma. Change in the size of the soft tissue
mass is easily evaluated on MRI and is a reliable indicator
of tumour response [105]. Dynamic MRI is not as reliable
as in osteosarcoma, as remaining small tumour foci may not
be detected. Sequential ﬂuorodeoxyglucose PET (FDG PET)
evaluation may be of additional value [34].
Progressive disease whilst on chemotherapy may man-
date changes in treatment or earlier primary local control
measures. An increase in the size of a tumour may, however,
be due to necrosis rather than tumour progression.
9.Followup
Followup is designed to detect either local recurrence or
metastatic disease at a time when early treatment is still
p o s s i b l ea n dm i g h tb ee ﬀective [34]. Followup of high
grade tumours should include both a physical examination
of the tumour site and assessment of the function and
possible complications of any reconstruction. Local and
chest imaging should be the norm. Evidence of optimum
frequency of followup and the best imaging investigations is
still lacking [34].
For high-grade tumors, current protocols recommend
follow up intervals of 2–4 months for the ﬁrst 3 years after
completion of therapy, every 6 months for year 4 and 5 and
thereafter annually [2, 3].
For low-grade bone sarcomas, the frequency of followup
visits may be reduced to 4–6 monthly for 2 years and then
annually. Late metastases as well as local recurrences and
functional deﬁcits may occur >10 years after diagnosis in all
tumours, and there is no universally accepted stopping point
for tumour surveillance [56].
It is important to evaluate the long-term toxicity eﬀect
of chemotherapy and radiotherapy as well as immedi-
ate chemotherapy related complications [43]. Monitoring
for late eﬀects should be undertaken, depending on the
chemotherapy protocol and radiation used and in conjunc-
tion with late eﬀect services when available [54, 106, 107].
Secondary cancers may arise in survivors of bone
sarcomas, either related to or independent of irradiation.
Secondary leukaemia, particularly acute myeloid leukaemia,
m a yr a r e l yb eo b s e r v e df o l l o w i n gc h e m o t h e r a p ya se a r l ya s
2–5 years after treatment [108, 109].
10. Key Recommendations
(i) The most common symptom of a primary bone
tumour is pain which may be non mechanical or
nightpain. The presenceofbone pain atnightshould
always be considered to be a “red ﬂag” symptom
leading to further investigation. The presence of pain
or a palpable mass arising from any bone should
cause concern and lead to further investigation of
whichaplain X-ray istheﬁrstinvestigation ofchoice.
(ii) The presence of radiological features including bone
destruction,newboneformation,periostealswelling,
and soft-tissue swelling are suggestive, but not diag-
nostic of a bone tumour and should also lead to
further investigation.Sarcoma 11
(iii) All bone tumour patients with clinicoradiological
ﬁndings suggestive of a primary bone tumour should
be sent to a reference centre.
(iv) The deﬁnitive diagnostic test is a biopsy. The biopsy
of a suspected primary malignant bone tumour
should be carried out at the reference centre by the
surgical team who are to carry out the deﬁnitive
tumour resection.
(v) The pathologist reporting on both the diagnosis and
resection of bone sarcomas should be an accredited
bone tumour pathologist and part of a bone sarcoma
multidisciplinary team (MDT). The report should
comply with guidance from the Royal College of
Pathologists.
(vi) In every case, the diagnosis must be conﬁrmed by
reference to clinical ﬁndings, laboratory investigation
and, in particular, radiological imaging at a bone
sarcoma MDT, this will minimise the risk of errors
in diagnosis and management. All patients should
have tissue stored for subsequent investigation with
appropriate consent.
(vii) Patientsshouldhavetheircaremanagedatareference
centre by a fully accredited MDT. The MDT should
make the decision about chemotherapy but may
delegate the responsibility to another centre. All
surgery should be carried out at a specialist bone
sarcoma centre.
(viii) Curative treatment for high-grade osteosarcoma
consists of surgery and chemotherapy. All patients
should be considered for inclusion into national or
international clinical trials.
(ix) Treatment for recurrent osteosarcoma is primarily
surgical, be it local recurrence or metastatic. The role
of second-line chemotherapy for recurrent osteosar-
coma is less well deﬁned than that of surgery and
there is no accepted standard regimen.
(x) For Ewing sarcoma, systemic treatment with
chemotherapy is standard. Where possible, surgery is
preferred for local control over radiotherapy alone.
(xi) Management of chondrosarcoma is surgical excision
with wide margins for all but low-grade central limb
chondrosarcoma where curettage may be adequate.
There are no data to support the routine use of
chemotherapy.
(xii) Standard follow up for all sarcoma cases is currently
chest X-ray and clinical review. The role of regular-
cross sectional imaging remains uncertain.
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